FDA allowing more e-cigarettes and nicotine pouches blindsides tobacco officials
FDA's new enforcement discretion guidance allows unauthorized e-cigarettes and nicotine pouches onto U.S. market before full regulatory vetting.
Objective Facts
Senior FDA officials in the tobacco center were blindsided by a recent decision that opens the door to allowing more unauthorized electronic cigarettes and nicotine pouches onto the U.S. market, with the guidelines allowing companies to launch certain nicotine-based products before they've been fully vetted by regulators. Some FDA officials tasked with enforcing vaping regulations were not consulted on the changes and only learned of them the night before the document was published. The six-page memo breaks with longstanding FDA policy requiring scientific verification of health benefits for smokers before any new products are introduced. The mango- and blueberry-flavored products were finally OK'd during Makary's last full week heading the FDA, just days before the agency posted the new guidelines allowing unauthorized nicotine products.
Left-Leaning Perspective
Ranjana Caple, director of federal advocacy for the American Lung Association, told The Hill that 'The timing of this guidance raises serious concerns about priorities and commitment to protecting kids.' The Utica Phoenix report highlighted that the move bypassed legally required public comment periods and blindsided senior agency officials, noting that Brian King of the Campaign for Tobacco-Free Kids stated this policy signals a 'broader opening to flavored products,' a concern shared widely across the public health community. Mitch Zeller, who retired as FDA's tobacco director in 2022, raised the pointed question to the AP of whether 'true subject matter experts may have actually opposed this policy and were ordered to do it anyway,' stating it undermines 'the ability of the public to have trust and faith in institutions like FDA.' Health advocates emphasize that nicotine addiction is not an adult-only problem, the adolescent brain is particularly vulnerable to nicotine's effects, and flavored products in mango, mint, or grape are not designed with adult smokers in mind, with health advocates making this point plainly for years. The American Lung Association's Caple added that the agency seems to be 'waving the white flag rather than restoring order to the marketplace,' the guidance effectively allows companies to keep illicit products on the market, and normalizing illicit products is fundamentally the wrong response when the proper answer is strengthening agency capacity. The Utica Phoenix notes the FDA made a sweeping decision without public input, quietly released new guidance allowing companies to sell certain e-cigarettes and nicotine pouches before completing full regulatory review, and the move bypassed legally required public comment periods. Democratic Sen. Dick Durbin commended Makary for standing up to Trump, saying 'I voted for Dr. Makary to head the FDA based upon his commitment to say no if President Trump asked him to do something that would harm America. Dr. Makary kept his word. He resisted Trump's plan to expose millions of children to the dangers of vaping.'
Right-Leaning Perspective
A Reason article stated that Makary's resistance to the policy "let his emotions override his avowed commitment to following the science" on tobacco harm reduction. The article noted that 'Given Makary's unsupported alarm about supposedly rampant adolescent nicotine addiction, it is perhaps not surprising that he resisted delivering on Trump's promise,' and criticized his reaction to the Glas product approvals as difficult to understand because the FDA's 'rigorous, scientific review' found the applicant 'sufficiently demonstrated' that Glas's device access restriction technology 'is expected to effectively mitigate the ability of youth to use the product.' The Vaping Post published commentary stating that harm reduction policies work better than prohibition-driven regulation, tobacco harm reduction experts recognize 'the urgent need to reduce smoking-related disease,' and this represents 'recognition that realistic harm reduction policies work better than prohibition-driven nicotine regulation.' Harm reduction experts quoted argue that 'the FDA is finally recognising that the current system has not kept up with consumer demand, new technology, or the urgent need to reduce smoking-related disease,' highlighting that the agency acts as if consumer behavior happens in isolation while ignoring illegal markets and how vaping has helped people move away from smoking. Jonathan Foulds, a tobacco-addiction specialist at Penn State University, told sources that 'The reality is they're just deluged by illegal products coming across the border,' and that the new enforcement approach is 'making it clear what should be common sense: We're going to focus on the worst actors.' The FDA's own statement justifying the policy notes 'More than 25 million Americans still smoke combustible cigarettes, and they deserve better, less harmful alternatives,' and this view matches growing international evidence that smoke-free nicotine products can help people quit smoking and reduce harm.
Deep Dive
The FDA's new enforcement discretion policy represents a fundamental shift in how federal regulators approach unauthorized vaping products, driven by the confluence of three factors: a massive FDA enforcement backlog (unauthorized products comprise 80% of the market), documented decline in youth vaping rates from 27.5% in 2019 to 5.2% in recent years, and intense political pressure from the Trump administration and the tobacco industry, which contributed millions to Republican causes. The six-page guidance breaks with longstanding FDA policy requiring scientific verification of health benefits before products are introduced and sparked internal confusion because officials tasked with enforcing vaping regulations were not consulted and only learned of it the night before publication. Each perspective captures genuine aspects of this policy tension. Health advocates are correct that the FDA bypassed required public comment periods and that proceeding without internal expertise consultation represents a departure from standard regulatory process—Mitch Zeller's concern that 'subject matter experts may have actually opposed this policy and were ordered to do it anyway' highlights legitimate questions about institutional integrity. Meanwhile, harm reduction advocates have a valid point that the FDA's previous enforcement approach failed to prevent unauthorized products from dominating 80% of the market, and most health researchers do agree e-cigarettes are significantly less harmful than traditional cigarettes. The core disagreement is whether these constraints justify a fundamental policy reorientation without the usual stakeholder input. Additionally, the claim that youth vaping is "at epidemic levels" (Makary's framing) conflicts with documented data showing dramatic decline, though health advocates correctly note that younger brains remain more vulnerable to nicotine regardless of prevalence trends. Unresolved questions going forward include: whether the promised FDA list of products eligible for enforcement discretion will materialize and what products will appear on it; whether large tobacco companies will actually dominate approvals under this framework or whether the policy enables smaller producers to compete; whether removing enforcement pressure on flavored products will measurably increase youth uptake despite recent declines; and whether focusing enforcement on illegal imports from China (which account for 70-80% of unauthorized sales) will prove feasible given previous resource constraints.